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Themechanisms bywhich trisomy 21 leads to the characteristic Down syndrome (DS) phenotype are unclear.We usedwhole genomemicroarrays
to characterize for the first time the transcriptome of human adult brain tissue (dorsolateral prefrontal cortex) from seven DS subjects and eight
controls. These data were coanalyzed with a publicly available dataset from fetal DS tissue and functional profiling was performed to identify the
biological processes central to DS and those that may be related to late onset pathologies, particularly Alzheimer disease neuropathology. A total of
685 probe sets were differentially expressed between adult DS and control brains at a stringent significance threshold (adjusted p value (q) b 0.005),
70% of these being up-regulated in DS. Over 25% of genes on chromosome 21were differentially expressed in comparison to amedian of 4.4% for all
chromosomes. The unique profile of up-regulation on chromosome 21, consistent with primary dosage effects, was accompanied by widespread
transcriptional disruption. The critical Alzheimer disease gene, APP, located on chromosome 21, was not found to be up-regulated in adult brain by
microarray or QPCR analysis. However, numerous other genes functionally linked to APP processing were dysregulated. Functional profiling of
genes dysregulated in both fetal and adult datasets identified categories including development (notably Notch signaling andDlx family genes), lipid
transport, and cellular proliferation. In the adult brain these processes were concomitant with cytoskeletal regulation and vesicle trafficking
categories, and increased immune response and oxidative stress response, which are likely linked to the development of Alzheimer pathology in
individuals with DS.
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around 1 in 800 live births in the human population. It is
caused by a complete, or occasionally partial, triplication of
chromosome 21 resulting in a complex and variable phenotype.
The disorder is primarily characterized by cognitive and
language dysfunction coupled with sensory and neuromotor
deficits and a neuropathology primarily characterized by de-
creased brain size and weight plus abnormal gyrification and
neurogenesis [1,2]. In addition, DS individuals are likely to
suffer from a broad range of symptoms outside of the nervous
system, including abnormal craniofacial development, con-
genital heart problems [3], and immune defects [4]. Two main⁎ Corresponding author. Fax: +44 1223 334162.
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doi:10.1016/j.ygeno.2007.08.005hypotheses are currently proposed to explain the mechanism by
which trisomy 21 leads to the DS phenotype [5]. The develop-
mental instability theory suggests that dosage imbalance on
chromosome 21 as a whole disrupts diverse developmental
pathways [6], while the gene-dosage hypothesis suggests that
dosage increase for specific genes on chromosome 21 con-
tributes more directly to different aspects of the disease pheno-
type [7].
Global gene expression profiling techniques are well suited
to the investigation of the effects of trisomy 21 because the
expression levels of trisomic genes as well as those in the
wider genome can be assessed. Recently, gene expression
profiling of brain and other tissues from human subjects with
trisomy 21 and from mice trisomic for homologous regions has
been performed to characterize the DS transcriptome. The
majority of studies use mouse models for trisomy 21, which
have partial triplications and display some characteristic
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studies using human DS tissues have been conducted, profiling
fibroblasts [15], whole blood [16], T cells [17], amniocytes
[18], and placenta [19], but most have lacked statistical power.
Only one group, using fetal samples, has previously investi-
gated global gene expression patterns in human DS brain
[20,21].
These studies have established a primary gene dosage effect
for chromosome 21 but it remains unclear whether there are
pervasive secondary transcriptional effects throughout the ge-
nome. The proportion of trisomic genes reported to show
increased expression levels and the degree of up-regulation also
vary between studies. The regulation and expression of chromo-
some 21 genes is likely to be both dynamic and complex
[22–24], and thus it is important that further global gene
expression studies with high statistical power are performed to
characterize the DS transcriptome fully.
In this study, we chose to investigate the transcriptome of
human adult DS brain. DS is classically characterized as a
developmental disorder, and for this reason the majority of
molecular studies have been performed on fetal tissue.
However, another notable feature of DS is precocious aging,
and numerous brain pathologies develop specifically in later
life, including calcification of the basal ganglia [25], an
increased risk of psychiatric disease [26], and the inevitable
development of Alzheimer disease (AD) pathology, character-
ized by neuronal loss and the presence of amyloid plaques and
neurofibrillary tangles. Overexpression of the amyloid pre-
cursor protein (APP) gene on chromosome 21 has been
proposed as the central event leading to AD pathology in DS
[1,2], in keeping with the amyloid cascade hypothesis [27,28],
but evidence suggests that triplication of this gene alone is not
sufficient for the development of AD pathology [29].
Investigation of the adult DS brain is therefore of interest not
only in the context of Down's syndrome itself, but also to
further our understanding of the mechanisms of later onset
pathologies such as that of AD. The study of the disorders in
this context presents a particular challenge, however, as inter-
pretation of results may be hampered by the inability to dis-
tinguish the fundamental effects of DS from the effects of AD
pathology per se.
We used microarrays to investigate the effect of trisomy on
the expression of genes on chromosome 21 and the wider
transcriptome in the adult DS brain, using tissue from the
dorsolateral prefrontal cortex. In addition, we coanalyzed and
compared a publicly available microarray dataset from fetal
DS brain [20], to identify (1) robust transcriptional alterations,
which are detected in both fetal and adult brain and are thus
likely to be present from an early stage throughout the
lifetime of DS individuals, and (2) those alterations that are
associated with the development of late onset pathologies
such as AD in the adult. Functional profiling of the set of
genes altered in the DS brain using annotation data from the
Gene Ontology Consortium [30] was conducted to investigate
the biological processes that are affected in DS and help
interpret how changes in gene expression can contribute to the
phenotype.Results
Identification of differentially expressed genes
Analysis of gene expression in the adult DS dorsolateral
prefrontal cortex was performed using seven DS samples and
eight control samples that passed our stringent quality control
procedures. Using a Bayesian-moderated t test and Benjamini–
Hochberg correction to control the false discovery rate (see
Materials and methods), over 5000 probe sets were found sig-
nificantly altered (adjusted p value (q) b 0.05) in the DS subjects
compared to controls. Due to this large number of altered probe
sets, we compared the results using three different significance
levels (0.05, 0.01, and 0.005) to classify differentially expressed
probe sets, which revealed several interesting trends. First, the
proportion of up-regulated probe sets increased with decreasing
q value (Fig. 1a); second, the proportion of up-regulated probe
sets on chromosome 21 increased with decreasing q value,
reaching 98% at q b 0.005 (Fig. 1a); third, probe sets localized to
chromosome 21 were overrepresented among the most sig-
nificant genes and this trend was unique to chromosome 21
(Fig. 1b). As overexpression of chromosome 21 genes is the
expected consequence of trisomy 21, these results demonstrate
clear disease effects at the lower significance thresholds and
indicate sufficient statistical power with our sample size.
A significance threshold of q b 0.005 was used to filter the
list of differentially expressed probe sets for further analysis;
685 probe sets were significantly altered, with 473 (69%) up-
regulated in DS compared to controls and 212 (31%) down-
regulated. These probe sets represented 400 up-regulated and
163 down-regulated genes. The bias toward up-regulation at
this significance threshold is only partially explained by up-
regulation on chromosome 21 and may therefore be a feature of
DS.
Effects of demographic variables on gene expression
The effect of demographic variables on differential gene
expression was assessed to determine whether factors other than
disease status could explain the results. This was particularly
important in this study as the increased power gained from the
use of six additional control samples was offset by the groups
being less well matched for known demographic variables
(Supplementary Table 1). The mean age of subjects in the
disease group was 58.6 ± 9.4 years and that of the control group
was 47.8 ± 10.8 years (p = 0.06, Student's t test). For the four DS
patients with data available for postmortem interval (PMI), mean
PMI was 14 ± 8 h compared to 26 ± 11 h for the eight controls
(p = 0.07, Student's t test). Gender was approximately evenly
split in the DS group (four females and three males) but not in the
controls (one female, seven males). For these variables to be
confounding factors in this study, they should not only vary
systematically between control and disease groups, but should
also show some correlation with the expression of one or more of
the differentially expressed genes. For the continuous variables
age and PMI, Pearson's correlation test was used to measure
correlation with gene expression, and Benjamini–Hochberg
Fig. 1. Characteristics of the Down syndrome (DS) dataset at different significance thresholds. (a) The percentage of significantly altered probe sets that were up- and
down-regulated at three significance thresholds for all chromosomes and for chromosome 21. An overall bias toward up-regulation is revealed at the lower thresholds
when all significant probe sets are considered. For chromosome 21 probe sets, a strong bias toward up-regulation is observed at all thresholds, but is most pronounced
at q b 0.005, at which 98% were up-regulated in DS. (b) The proportion of significant probe sets localized to each chromosome at three significance thresholds and in
the genome as a whole. Chromosome 21 is highlighted in red and shows a unique trend of comprising a greater proportion of the significant probe sets as the
significance threshold decreases. For all other chromosomes, representation at each significance threshold is relatively consistent and comparable to the percentage of
all human genes localized to them.
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results for either age or PMI (smallest q values were 0.10 and
0.24, respectively). For the categorical variable of gender, the
LIMMA package from Bioconductor was used to fit a linear
model to detect differential gene expression between male and
female samples. Again, no significant differences were found
following Benjamini–Hochberg correction for multiple testing
(smallest q = 0.63). These results indicate that these demo-
graphic factors did not have a significant influence on the
observed gene expression changes.
Gene expression on chromosome 21
Chromosome 21 is currently estimated to contain 352 genes
(NCBI human genome build 36), about 50 of which form two
large clusters of keratin-associated proteins that are not
represented on the Affymetrix HG-U133A chip due to high
sequence similarity. A further 53 predicted genes with the prefix
“LOC” are also not represented on the chip. After filtering for
Class A probe sets (see Materials and methods) there are 238
probe sets on the HG-U133A chip that target 145 unique and
generally well-characterized chromosome 21 genes. The firstkey question of this study is how many trisomic genes show
increased expression at the mRNA level in adult DS subjects.
There were 46 significant probe sets targeting genes localized to
chromosome 21, and 45 of these were up-regulated in DS. There
are often multiple probe sets for a given gene on Affymetrix
microarrays and in a few instances 2 or more significant probe
sets were found for the same gene (Table 1). Redundant probe
sets can distort the calculation of the percentage of genes on a
chromosome that is differentially expressed and therefore only
the most significant probe set for each gene was retained. After
redundant probe sets were excluded there were 39 up-regulated
genes and 1 down-regulated gene on chromosome 21 (q b 0.005,
Table 1) and hence 27% (39/145) of trisomic genes investigated
in this study were found to be overexpressed. To see how this
compared to other chromosomes, the percentage of differentially
expressed genes was similarly calculated for all other chromo-
somes. It ranged from 3.0% (chromosomes 16 and Y) to 6.6%
(chromosome 8) and the median was 4.3% (Fig. 2). Thus
chromosome 21, with 27% of genes showing significant changes
in expression, had by far the highest proportion of significantly
altered genes. All but 1 of the significant genes on chromosome
21 were up-regulated and this pattern was not seen on other
Table 1
Chromosome 21 genes significantly altered in adult DS brain and corresponding results in the fetal brain dataset
Gene name Gene
symbol
Entrez
gene ID
Adult DS brain Fetal DS brain Original fetal analysis
Significant
probe sets/
total probe
sets on chip
Fold
change
Adjusted
p value
(b0.005)
Fold
change
Adjusted
p value
(b0.3)
Fold
change
(cerebrum)
Adjusted
p value
(b0.05)
Cystatin B (stefin B) CSTB 1476 1/1 2.15 0.0003 1.61 0.10 1.69 7.8×10−5
Transmembrane protein 50B TMEM50B 757 1/1 2.53 0.0003 1.50 0.28
Down syndrome critical region gene 3 DSCR3 10311 1/2 1.61 0.0003 1.14 0.29 1.82 1.4×10−5
Pituitary tumor-transforming 1 interacting protein PTTG1IP 754 1/1 2.79 0.0006 1.75 0.06 1.52 1.5×10−7
SON DNA binding protein SON 6651 4/4 1.75 0.0006 1.52 0.21 1.39 7.3×10−4
Transmembrane protein 1 TMEM1 7109 1/2 1.94 0.0011 1.36 0.20 1.22 5.3×10−4
Protein arginine methyltransferase 2 PRMT2 3275 2/4 1.69 0.0013 1.48 0.10 1.37 3.6×10−3
Junctional adhesion molecule 2 JAM2 58494 1/1 1.85 0.0016 1.39 0.28 Not significant
Phosphatidylinositol glycan anchor biosynthesis, class P PIGP 51227 1/1 2.08 0.0018 1.69 0.12 Not significant
BTB and CNC homology 1, basic leucine zipper
transcription factor 1
BACH1 571 1/2 1.77 0.0018 1.16 0.28 Not significant
ATP-binding cassette, subfamily G (WHITE), member 1 ABCG1 9619 1/2 2.67 0.0018 1.10 0.29 Not significant
BTG family, member 3 BTG3 10950 2/3 2.48 0.0018 1.69 0.28 Not significant
Chromosome 21 open reading frame 25 C21orf25 25966 1/1 1.78 0.0018 Not significant Not significant
SH3 domain binding glutamic acid-rich protein SH3BGR 6450 1/1 1.62 0.0019 Not significant 2.17 7.1×10−7
Ubiquitin-specific peptidase 16 USP16 10600 1/1 2.12 0.0019 1.81 0.06 1.68 5.3×10−4
Integrin, β2 (antigen CD18 (p95), lymphocyte
function-associated antigen 1; macrophage
antigen 1 (mac-1) β subunit)
ITGB2 3689 1/1 2.93 0.0020 Not significant Not significant
High-mobility group nucleosome binding domain 1 HMGN1 3150 2/2 1.62 0.0021 1.40 0.28 Not significant
U2 (RNU2) small nuclear RNA auxiliary factor 1 U2AF1 7307 1/1 1.26 0.0023 1.29 0.29 Not significant
Regulator of calcineurin 1 RCAN1 1827 1/3 1.70 0.0023 Not significant
Zinc finger protein 294 ZNF294 26046 1/1 1.80 0.0023 1.82 0.06 1.71 3.4×10−5
T cell lymphoma invasion and metastasis 1 TIAM1 7074 1/2 1.55 0.0023 1.90 0.07 Not significant
Dual-specificity tyrosine-(Y)-phosphorylation
regulated kinase 1A
DYRK1A 1859 1/3 1.62 0.0024 1.61 0.15 Not significant
V-ets erythroblastosis virus E26 oncogene-like (avian) ERG 2078 1/2 1.50 0.0024 Not significant Not significant
ADAM metallopeptidase with thrombospondin
type 1 motif, 1
ADAMTS1 9510 1/1 3.70 0.0024 Not significant Not significant
MORC family CW-type zinc finger 3 MORC3 23515 1/1 1.61 0.0025 1.52 0.28 Not significant
SAM domain, SH3 domain, and nuclear
localization signals, 1
SAMSN1 64092 1/1 1.67 0.0027 Not significant Not significant
Cystathionine-β-synthase CBS 875 1/1 1.78 0.0027 1.40 0.28 Not significant
Chromosome 21 open reading frame 59 C21orf59 56683 1/1 1.47 0.0027 1.45 0.10 Not significant
Ribosomal RNA processing 1 homolog B (S. cerevisiae) RRP1B 23076 1/2 1.67 0.0028 2.00 0.28 Not significant
Chromosome 21 open reading frame 66 C21orf66 94104 1/2 1.79 0.0029 1.51 0.28 Not significant
MCM3 minichromosome maintenance-deficient 3
(Saccharomyces cerevisiae)-associated protein
MCM3AP 8888 1/3 1.41 0.0032 1.74 0.10 Not significant
Mitochondrial ribosomal protein L39 MRPL39 54148 1/1 1.67 0.0032 1.35 0.26 1.44 7.5×10−4
Crystallin, ζ (quinone reductase)-like 1 CRYZL1 9946 1/1 1.66 0.0036 1.55 0.28 Not significant
S100 calcium binding protein, β (neural) S100B 6285 1/1 2.28 0.0037 Not significant Not significant
Leucine-rich repeat-containing 3 LRRC3 81543 1/1 −1.39 0.0038 −1.11 0.29 Not significant
Phosphofructokinase, liver PFKL 5211 1/2 1.32 0.0038 1.25 0.28 1.16 1.9×10−4
Intersectin 1 (SH3 domain protein) ITSN1 6453 1/6 2.20 0.0038 1.46 0.28 Not significant
Neural cell adhesion molecule 2 NCAM2 4685 1/2 1.47 0.0038 Not significant Not significant
Collagen, type VI, α 2 COL6A2 1292 1/2 2.56 0.0040 Not significant Not significant
Carbonyl reductase 1 CBR1 873 1/1 1.97 0.0047 Not significant Not significant
Chromosome 21 genes significantly altered in adult DS brain are listed (qb0.005) together with the corresponding result for each gene in our reanalysis of the fetal
brain dataset and in the original analysis of Mao et al. [21].
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changes are a direct consequence of the triplication of these
genes in DS. Significantly up-regulated genes on chromosome
21 generally reflected the 1.5-fold increase in expression pre-
dicted by the gene-dosage hypothesis (Fig. 3). However, the
median increase in expression was slightly higher at 1.76-fold
and 6 genes had fold changes in excess of 2.5.Distribution of differentially expressed genes on
chromosome 21
To assess how the 40 significant genes localized to chromo-
some 21 were distributed, histogram plots showing the density
distributions of (i) all chromosome 21 genes, (ii) those re-
presented on the HG-U133A chip, and (iii) those that were
Fig. 2. The percentage of genes on each chromosome that were significantly altered in DS at the significance threshold q b 0.005. Over a quarter of the genes localized
to chromosome 21 were significantly altered compared to a median of 4.4% for all chromosomes. These data support a primary dosage effect on chromosome 21
accompanied by widespread transcriptional disruption in adults with DS.
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the HG-U133A chip show a density distribution very similar to
that of all chromosome 21 genes (Supplementary Fig. 1),
indicating no inherent bias in the locations of the subset of genes
represented on the chip. The density distribution of significant
chromosome 21 genes was then compared to that of the genes
represented on the chip. This revealed that the significantly
altered genes were quite evenly distributed along the chromo-
some, relative to the underlying distribution (Fig. 4). These data
suggest that primary gene dosage effects are found throughout
chromosome 21 and do not cluster at particular locations, in
agreement with Mao et al. [21].
Quantitative real-time PCR (QPCR) analysis
QPCRwas performed to validate the altered expression levels
of 11 selected genes, using cDNA derived from total RNA of the
brain tissue samples. These included 6 chromosome 21 genes
that showed significant up-regulation by microarray (q b 0.005);
3 were confirmed with QPCR (ADAMTS1, BACE2, PTTG1IP;
p b 0.05), while a trend toward up-regulation was observed for
S100B (p = 0.07), RCAN1 (p = 0.13), and DYRK1A (p = 0.17)
(Fig. 5). A surprising result from the microarray study was that
expression of APP, thought to be critical for the development of
Alzheimer pathology in DS, was not significantly increased,
although one probe set showed a trend for up-regulation
(q = 0.06). APP expression was therefore investigated using
QPCR, which confirmed the negative microarray result (Fig. 5).
The final chromosome 21 gene investigated by QPCR was
ADARB1, which the microarray analysis indicated as down-
regulated, albeit at the less stringent 0.05 significance level. In
all, 8 chromosome 21 genes were decreased at this significance
level in the adult brain as well as showing down-regulation in the
fetal brain dataset (see below), and we therefore wanted to
confirm if trisomic genes could be down-regulated in DS. In fact,
ADARB1 showed a significant up-regulation by QPCR (Fig. 5).
Further investigation of other genes is required before firm
conclusions regarding the down-regulation of trisomic genes onchromosome 21 can be drawn, but the QPCR result suggests that
it may be an unlikely phenomenon.
Three genes not located on chromosome 21 that were
significantly up-regulated in the microarray study were also
investigated by QPCR, two of which were confirmed to be up-
regulated in DS (APOE and NOTCH2; Fig. 5). The third gene,
APPBP2, failed to validate using QPCR, showing no difference
in expression between DS and control groups (Fig. 5); because
QPCR probes were chosen to target similar transcripts to the
microarray probe-sets, it is unlikely that the failure to confirm
up-regulation of APPBP2 was due to differential expression of
alternative transcripts of this gene and thus may indicate that the
microarray finding was a false positive.
Full details of the fold changes and associated p values for
microarray data and QPCR data are given in Supplementary
Table 2. Fold changes were reasonably consistent between
microarray and QPCR data, although in the case of PTTG1IP a
2.8-fold increase in expression in the DS group was found by
microarray compared to a 6.4-fold increase measured with
QPCR. Increases exceeding 2-fold for several chromosome 21
genes (ADARB1, ADAMTS1, BACE2, and PTTG1IP) were
found by QPCR, confirming that some genes are up-regulated to
a greater extent than the predicted 1.5-fold.
Comparison with proteomics data
As further validation and indication that at least some changes
at the transcript level affect protein expression levels, a number
of genes identified as differentially expressed by microarray
were also found to be dysregulated at the protein level in a
parallel study. A previous study from this laboratory [31] used
two-dimensional fluorescence difference in-gel electrophoresis
(2D-DIGE) to investigate the protein profile of brain tissue from
the same DS individuals. 2D-DIGE is capable of resolving
around 2500 proteins, mainly abundant soluble proteins. This
study revealed 33 differentially expressed proteins between DS
and controls, all of which showed increased expression in DS. A
large proportion of these were identified as being functionally
Fig. 3. Fold changes for the 46 probe sets significantly altered in DS (q b 0.005)
that map to chromosome 21. The 46 probe sets represent 40 unique genes; 2
significant probe sets detecting BTG3, HMGN1, and PRMT2 were identified, as
well as all 4 probe sets targeting SON. The theoretical 1.5-fold increase in
expression is indicated by the dashed line and some genes show substantial
deviation from a simple dosage increase. Only one gene localized to
chromosome 21, LRRC3, showed decreased expression (fold change b1) in
DS patients.
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Of these 33 proteins, 9 had at least one significantly up-regulated
transcript at q b 0.005 and a further 6 at q b 0.05 (Supplementary
Table 3). In the case of dynamin, it was not possible to
distinguish the different isoforms at the protein level, but the
transcript data suggest that DNM1 is decreased and DNM2 is
increased. Only one protein, CLTC, was found to be down-
regulated at the transcript level (q = 0.03) but was previously
found up-regulated at the protein level.
Comparison with fetal DS brain
A comparison of expression data from adult and fetal brain
tissue was performed to explore further the gene expression
changes observed in DS. A publicly available dataset for the
human fetal DS brain (cerebrum) was reanalyzed using the same
statistical approach employed for the adult brain, allowing a
direct comparison of the two datasets (see Materials and
methods). In our reanalysis, only one probe set was significant
at q b 0.05, but as the top 22 probe sets represented chromosome
21 genes and all were up-regulated, we considered it reasonable
to relax the significance threshold. At q b 0.25, 41 probe sets
were significant, rising dramatically to 3725 at q b 0.3. The
relatively high q values may be due to the smaller sample size in
the fetal dataset (four DS and seven control subjects) reducing
statistical power. At q b 0.3, the reanalysis identified 25 of the 26
chromosome 21 probe sets reported by Mao et al. [21] (18 at
q b 0.25), in addition to many others that did not pass the
significance criteria in the original analysis. After removing
redundant probe sets, we compared chromosome 21 genes that
were significant in the adult DS brain at q b 0.005 to those
significant in the fetal DS brain at q b 0.3. Twenty-eight genes
were up-regulated in both the adult and the fetal DS brain and
represent independent findings in human tissue (Table 1). Only
11 of these were reported in the original analysis by Mao et al.
[21].
Functional profiling
Functional profiling of the 685 probe sets differentially
expressed in DS (q b 0.005) using Onto-Express revealed 31
Gene Ontology (GO) categories significantly overrepresented
in the list of up-regulated genes and 14 GO categories
overrepresented among the down-regulated genes (Table 2).
These individual categories could be further classified into
several major groups: among up-regulated genes, enriched
processes included immune system function, development, cell
cycle/proliferation, cytoskeleton and vesicle trafficking, cell
signaling, and regulation of gene expression as well as lipid
transport and response to oxidative stress. Other cell signaling
categories, synaptic transmission, muscle-related, and develop-
mental processes were enriched among down-regulated genes.
The presence of AD pathology in the adult DS brain is usually
considered a confounding effect; however, by focusing solely on
fetal tissue the pathogenesis of later-developing features such as
AD pathology cannot be assessed. By comparing the adult and
fetal datasets, we aimed to distinguish those processes that are
Fig. 4. Distribution of significant genes across chromosome 21. Density distributions for the 145 chromosome 21 genes represented on the HG-U133A chip and for the
40 that were found significantly altered in DS are shown. The histograms are divided into 1-Mb bins.
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brain from those that may arise as a result of late onset pathology,
particularly AD. We therefore also functionally profiled the
group of 179 probe sets that were altered in both adult (q b 0.005)
and fetal (q b 0.3) DS brain. This approach should identify
ongoing processes central to the DS phenotype and be
particularly robust as the individual genes have been identified
in two independent studies. Twelve significantly overrepre-
sented categories were identified, 11 of which were also found
when the adult changes were profiled separately (Table 3). Some
functional categories found dysregulated in the adult brain were
not found in the overlap between the fetal and the adult
dysregulated genes, notably immune response, response to
oxidative stress, and the majority of cytoskeletal/vesicle-related
categories. These may represent processes related to the late
onset pathologies that occur in DS.
Complete lists of the genes contributing to the significant GO
categories can be found in Supplementary Tables 4 and 5.
Discussion
It has been known for nearly half a century that DS is
caused by a chromosomal abnormality, namely the trisomy of
chromosome 21. Despite intensive research, the mechanisms
by which the extra copy of chromosome 21 leads to the DS
phenotype remain unclear. Only trisomies of human chromo-
somes 21, 18, and 13 are compatible with postnatal survival.
Chromosome 21 has the fewest number of genes of all human
autosomes and individuals with DS typically survive into late
middle age, whereas individuals with trisomy 13 or 18 rarely
survive more than a year. In DS the dosage imbalance for
chromosome 21 genes is thought to affect normal interactions,
for example, by altering the correct stoichiometry of protein
complexes; the downstream consequences may be widespread,
particularly in the case of transcription factor complexes [32].
However, others postulate that the overexpression of individual
genes on the trisomic chromosome makes a more importantcontribution to the phenotype than widespread transcriptional
disruption [7].
Using a variety of methods, including microarrays, QPCR,
and SAGE, previous studies have investigated the transcrip-
tional consequences of trisomy 21 in mouse models and human
tissues, establishing a primary gene dosage effect on chromo-
some 21 [8,10,18,20,21]. The issue of whether trisomy 21 has
secondary effects on transcription throughout the genome
remains unresolved as conflicting data have been reported by a
number of different studies [8–14,18,20,21]. Fundamental
differences between studies, including organism, tissue, and
developmental age studied, as well as technology and statistical
techniques used, have complicated the interpretation of these
findings. Grouping studies according to whether they found
pervasive secondary transcriptional changes does not reveal any
common factor, such as developmental age, or combination of
factors that might explain the contradictory findings.
The present study has shown up-regulation of a subset of
chromosome 21 genes in human adult DS brain, accompanied
by numerous transcriptional changes throughout the genome,
lending support to the theory that secondary transcriptional
changes occur as a result of trisomy 21. In contrast, the original
study of human fetal DS brain tissue concluded that few tran-
scriptional changes occur outside chromosome 21 [21].
However, our reanalysis of this dataset suggests that transcrip-
tional changes in the fetal brain may be more widespread than
previously thought. Nonetheless, the wider effects observed
throughout the genome in the adult brain could be the
cumulative effect of the many defects and pathologies
associated with DS. On chromosome 21, the gene expression
changes described here in the adult DS brain and by Mao et al.
[21] in the fetal DS brain are in broad agreement: a subset of
trisomic genes, distributed throughout chromosome 21, shows
increased expression relative to normal controls. Both studies
reveal a relatively small fraction of trisomic genes up-regulated
in human DS subjects, which is surprising given that the
majority are known to be expressed in brain [33,34]. This is,
654 H.E. Lockstone et al. / Genomics 90 (2007) 647–660however, consistent with other studies using human tissues
[15,16,18].
Trisomic genes that are not overexpressed may be subject to
dosage compensation; for example, the dosage effect could be
canceled if a transcriptional repressor were also at dosage
imbalance [35]. Such a mechanism has previously been
proposed in the mouse [11]. However, it seems unlikely that
such a high proportion of chromosome 21 genes would show
dosage compensation and there are several reasons the number
of trisomic genes showing up-regulation at the mRNA level inthe present study is likely to be underestimated. For example, of
the 39 chromosome 21 genes significantly overexpressed in DS
adult brain and the 23 genes in the fetal brain [21], only 11 were
reported increased by both studies (although a greater degree of
overlap was seen when the adult data were compared to the fetal
data reanalyzed in the same manner as the adult-derived
dataset). This inconsistency may reflect the biological conse-
quence of temporal patterns of gene expression and/or
regulatory mechanisms but it is possible that genes identified
in just one dataset represent false negatives in the other study
655H.E. Lockstone et al. / Genomics 90 (2007) 647–660and may reflect limits in the sensitivity and/or dynamic range of
microarrays. Taken together, the two studies may suggest that a
greater proportion of trisomic genes are overexpressed than in
either study alone. It is also of note that a further 23
chromosome 21 genes were up-regulated in our dataset at
q b 0.05, but did not meet the more stringent threshold used in
this study. A more specific analysis of chromosome 21 genes in
human DS brain tissue would be of interest.
In theory, the presence of an additional copy of chromosome
21 would lead to a dosage-dependent 1.5-fold increase in the
expression of all triplicated genes. Among some previous
studies, a consistent 1.5-fold increase in the expression of
trisomic genes has been reported [9,10,21], while others, in-
cluding a comprehensive QPCR study of the Ts65Dn mouse
model, have found substantial deviations from this theoretical
value [12,18]. These results may be due to differences in the
sensitivity of gene expression techniques, the individual genes
considered, and the complex nature of gene regulation.
In the present study, both the microarray and the QPCR
analyses of the adult DS brain showed that the degree of up-
regulation of trisomic genes was sometimes greater than the
predicted dosage effect of 1.5-fold. The previous study
investigating human fetal brain, on the other hand, found
genes consistently increased in expression by 1.5-fold [21]. Our
reanalysis of the fetal data, using the same statistical approach
applied to the adult data, confirmed that up-regulation of
chromosome 21 genes in the fetal brain fits the model
(1.54 ± 0.05), suggesting that the deviation seen in the adult
brain is not influenced by the statistical analysis. It is possible
that expression of trisomic genes fits closely with the dosage-
dependent model at the fetal stage, but that other changes over
the human life span impact on the expression profile.
The role of triplicated APP in DS and AD pathogenesis
An interesting feature of DS is the inevitable development of
Alzheimer pathology by around age 40. APP is encoded on
chromosome 21 and is an obvious candidate for the pathogenesis
of AD in DS individuals. This is supported by findings such as a
duplication of the APP locus, which causes autosomal dominant
early onset AD with cerebral amyloid angiopathy [36,37], and
that a 78 year old individual with a partial trisomy 21 excluding
the APP gene did not develop AD pathology [38]. However,
there have been both positive [39] and negative reports [2,40] of
overexpression of APP mRNA in DS, and other studies suggest
that overexpression of APP alone is insufficient for the develop-
ment of AD pathology [29].
Intriguingly, APP was not found to be significantly over-
expressed in our dataset nor in the original analysis of fetal brain
tissue by Mao et al. [21]. This result was confirmed in ourFig. 5. Selected genes were investigated by QPCR analysis of RNA from adult brain
RCAN1, DYRK1A, PTTG1IP, and S100B, plus non-chromosome 21 genes APPBP2, A
PGK1 (located on chromosome X). Five genes (ADAMTS1, BACE2, PTTG1IP, AP
(pb0.05, indicated by a double asterisk) and a further 3 genes (RCAN1, DYRK1A, S1
APP and APPBP2 failed to show significant dysregulation by QPCR; in the case of A
chromosome 21 gene ADARB1 showed significant up-regulation by QPCR but si
obtained from both microarray and QPCR data for these 11 genes can be found in Ssamples by QPCR but is nonetheless surprising. A number of
genes functionally linked to APP were found dysregulated at
q b 0.005 in adult DS brain, including the chromosome 21 genes
BACE2 and S100B (confirmed by QPCR) and apolipoproteins
APOE and CLU, plus PSEN1, PSEN2, and MAPT dysregulated
at q b 0.05 by microarray. The combination of these changes
suggests disturbances in the normal processing and function of
APP; however, the data also suggest that this may be a more
complex process than simple up-regulation of the mRNA. A
number of the processes revealed by functional profiling (see
below) suggest further candidates for the predisposition of the
DS brain to the buildup of amyloid β and development of AD
pathology and symptoms.
Functional profiling in adult and fetus
Among the biological process categories overrepresented in
the list of genes dysregulated in both fetal and adult datasets
were developmental pathways, lipid transport, cellular prolif-
eration, and transcriptional regulation. These processes are
likely to be important to the core DS phenotype and may
represent predisposing factors to late onset pathology.
Disruption of the lipid transport process may be important in
the context of brain development due to the important role lipids,
and especially cholesterol, play in synapse formation and
maintenance. This includes the regulation of functional proper-
ties of ion channels and transmitter receptors and control of
synaptic vesicle formation and transport [41], which could con-
tribute to abnormal cognitive development in DS individuals.
In the adult brain, early dysfunction in lipid transport may act
as a contributing factor to the buildup of amyloid β and
development of AD pathology. Of particular interest is the up-
regulation of APOE (confirmed by QPCR), which binds choles-
terol in astrocytes and regulates lipid transport into neurons via
the LDL and LRP1 receptors [42], both of which also showed
altered expression. The APOE4 allele is a well-characterized
risk factor for AD, which appears to influence the accumulation
of amyloidβ [43]. It would be of interest to investigate any effect
of APOE genotype status on the expression of APP in a larger
cohort. APOE is located on chromosome 19 and hence
represents a clear example of a factor that may predispose to
AD, but develops secondarily to the direct effects of trisomy 21.
Alterations in a large number of genes falling into the
category of development are unsurprising, given the develop-
mental nature of the disorder. Of particular interest is the down-
regulation of members of the distal-less family of genes, DLX2
(in our analysis of both fetus and adult) and DLX6 (in adult
only). Dlx family genes are important for the development of
forebrain GABAergic neurons [44], deficits in which have been
demonstrated in certain cortical layers of the DS brain [1]. Astissue, including the chromosome 21 genes ADAMTS1, ADARB1, APP, BACE2,
POE and NOTCH2. All genes were normalized to the endogenous control gene
OE, NOTCH2) were confirmed significantly up-regulated in Down syndrome
00B) showed a trend for up-regulation (p≤0.17, indicated by a single asterisk).
PP the lack of significant change was consistent with the microarray result. The
gnificant down-regulation by microarray analysis. Fold changes and p values
upplementary Table 2.
Table 2
Biological processes altered in adult Down syndrome brain
GO ID GO biological process category No. of significant
genes
No. of genes
on chip
Corrected
p value
Overrepresented among up-regulated genes
Immune system GO:0019884 Antigen presentation, exogenous antigen 4 12 0.001
GO:0019886 Antigen processing, exogenous antigen via MHC class II 4 13 0.001
GO:0019883 Antigen presentation, endogenous antigen 4 9 0.004
GO:0007229 Integrin-mediated signaling pathway 5 45 0.012
GO:0019885 Antigen processing, endogenous antigen via MHC class I 3 12 0.020
GO:0006955 Immune response 14 274 0.037
Developmental GO:0001709 Cell fate determination 3 6 0.002
GO:0016477 Cell migration 3 10 0.008
GO:0007219 Notch signaling pathway 3 19 0.021
GO:0016337 Cell–cell adhesion 3 30 0.035
GO:0009887 Organogenesis 4 55 0.035
Cytoskeletal/vesicle related GO:0006897 Endocytosis 8 65 0.002
GO:0006886 Intracellular protein transport 13 174 0.007
GO:0030036 Actin cytoskeleton organization and biogenesis 6 54 0.011
GO:0008360 Regulation of cell shape 3 18 0.013
GO:0051016 Barbed-end actin filament capping 3 21 0.019
GO:0016192 Vesicle-mediated transport 4 49 0.028
Cell cycle/proliferation GO:0007049 Cell cycle 16 211 0.004
GO:0006916 Anti-apoptosis 7 80 0.019
GO:0008285 Negative regulation of cell proliferation 9 127 0.023
GO:0001558 Regulation of cell growth 5 67 0.038
Cell signaling GO:0007173 Epidermal growth factor receptor signaling pathway 3 13 0.005
GO:0007169 Transmembrane receptor protein tyrosine kinase signaling pathway 7 65 0.009
Regulation of gene expression GO:0006338 Chromatin remodeling 3 20 0.017
GO:0045449 Regulation of transcription 5 63 0.034
GO:0006445 Regulation of translation 3 29 0.040
Other GO:0001503 Ossification 4 24 0.006
GO:0008015 Circulation 5 45 0.008
GO:0006869 Lipid transport 5 46 0.009
GO:0006730 One-carbon compound metabolism 4 29 0.009
GO:0006979 Response to oxidative stress 3 37 0.029
Overrepresented among down-regulated genes
Synaptic processes GO:0007268 Synaptic transmission 8 161 0.003
GO:0006813 Potassium ion transport 6 124 0.006
GO:0006812 Cation transport 5 121 0.021
Cell signaling GO:0006470 Protein amino acid dephosphorylation 7 107 0.004
GO:0007264 Small GTPase-mediated signal transduction 6 155 0.020
Muscle related GO:0008016 Regulation of heart contraction rate 3 21 0.002
GO:0006936 Muscle contraction 5 69 0.004
GO:0007517 Muscle development 5 111 0.018
Other GO:0007010 Cytoskeleton organization and biogenesis 6 52 0.001
GO:0008544 Epidermis development 4 60 0.006
GO:0006968 Cellular defense response 4 65 0.011
GO:0007605 Perception of sound 3 78 0.044
GO:0007275 Development 9 369 0.044
GO:0007283 Spermatogenesis 3 98 0.048
Details of the number of significant genes falling into each category, the total number of genes in that category represented on the chip, and the significance level are
given.
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been implicated in schizophrenia [45] and other psychiatric
disorders [46,47], dysregulation of Dlx genes may underlie not
only cognitive deficits but also the increased incidence of
psychiatric disorders in DS patients. Dlx genes are also essential
for craniofacial development [48] and thus are novel candidates
for further study in the genesis of the primary DS phenotype.
A further interesting group of developmental genes found
up-regulated relate to Notch signaling; increased expression ofthe NOTCH2 gene in DS was confirmed by QPCR. In
addition to numerous roles in early embryogenesis, Notch
signaling is important in CNS development and is also of
interest in the context of the development of AD pathology.
NOTCH1 protein is found up-regulated in AD [49], and more
recently, data from the Ts1Cje mouse model have implicated
Notch signaling in DS [9] with confirmation from human
samples [50]. Abnormal APP processing may explain the
downstream effects seen in Notch signaling as Notch and APP
Table 3
Biological processes overrepresented in the list of genes dysregulated in both fetal and adult brain
GO ID GO biological process category No. of significant
genes
No. of genes
on chip
Corrected
p value
GO:0006338 Chromatin remodeling 3 20 0.001
GO:0007275 Development 11 369 0.004
GO:0006869 Lipid transport 3 46 0.006
GO:0006886 Intracellular protein transport 7 174 0.006
GO:0007517 Muscle development 4 111 0.016
GO:0006357 Regulation of transcription from RNA
Pol II promoter
6 166 0.016
GO:0045449 Regulation of transcription 3 63 0.016
GO:0007169 Transmembrane receptor protein tyrosine
kinase signaling pathway
3 65 0.018
GO:0007283 Spermatogenesis 3 98 0.022
GO:0008285 Negative regulation of cell proliferation 4 127 0.027
GO:0005975 Carbohydrate metabolism 4 185 0.040
GO:0007049 Cell cycle 5 211 0.044
Details of the number of significant genes falling into each category, the total number of genes in that category represented on the chip, and the significance level are
given.
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is cross talk between the pathways via direct interaction of the
proteins [50]. We also found genes for the γ-secretase
components PSEN1 and PSEN2 dysregulated at q b 0.05 in
the adult DS brain. Furthermore, Notch signaling controls
cellular differentiation, apoptosis, proliferation, and migration
[52], all pathways we found dysregulated in adult DS brain. In
postmitotic neurons, Notch affects neurite extension [53,54]
and the actin cytoskeleton [52,55]; therefore, this pathway
may also contribute to neurodegenerative processes. If
systemic, Notch-mediated abnormalities in cell proliferation
and the actin cytoskeleton may underpin a number of the wide
range of health problems seen in DS individuals, including
leukemia and heart defects. The dysregulation of Notch and
Dlx are likely to be interrelated: loss of Dlx function leads to
an increase in Notch signaling [56], which mirrors the results
observed here in the adult brain. From these data, together
with a recent report of abnormal Notch signaling in DS [50],
Notch-related pathways emerge as a clear candidate for further
study in this disorder. Interestingly, a number of transcription
factors listed in the dysregulated category regulation of gene
expression (e.g., ID4, TCF12, TCFL5) are members of the
basic helix-loop-helix family, targeted by Notch signaling
[52]. Activation of major signaling pathways such as Notch
may underlie the spread of transcriptional dysregulation
throughout the genome.
In the adult brain the processes described above are
concomitant with disruption of those relating to cytoskeletal
regulation and vesicle trafficking, an increased immune re-
sponse, and response to oxidative stress. These processes, being
specifically altered in the adult DS brain, may be more likely to
relate to the late onset pathologies.
In particular, categories related to the cytoskeleton and
vesicle function/trafficking were overrepresented among up-
regulated genes, in good agreement with data obtained in a
parallel proteomics study of AD and DS brain tissue [31], and
may relate to synaptic degeneration. APP cleavage is linked withvesicle transport [57] and amyloid deposition is connected with
the accumulation of large synaptic vesicles in the perikaryon
[58,59]. Cytoskeleton organization and synaptic transmission,
however, were enriched among the down-regulated genes,
which suggests that despite the presence of enlarged vesicles
and/or activated vesicle recycling processes, these are unable to
compensate fully for deficits in synaptic function.
The genes dysregulated in immune-related categories point
toward an inflammatory state in the adult brain, which is likely to
be primarily linked to the development of AD pathology as these
geneswere not found dysregulated in the fetal brain. In the context
of AD pathology, amyloid β is an activator of inflammatory
processes. Additionally, the presence of inflammatory mediators
in the brainmay be a primary cause of damage to neurons [60,61].
It is of note that in the original analysis of data from fetal tissue
[21], MHC II genes were found up-regulated when fetal astro-
cytes were examined. Thus an underlying proinflammatory CNS
environment may exist in DS individuals [4], which is exa-
cerbated over time, concomitant with the buildup of amyloid β.
In summary, we report a gene expression profiling study of
Down syndrome, the first using human adult brain tissue, which
has identified hundreds of genes that are statistically signifi-
cantly altered in the disorder. The transcriptome of chromosome
21 was predominantly affected, displaying a unique profile of
up-regulation, and was accompanied by transcriptional changes
throughout the genome. It is not clear if these secondary effects
are the direct consequence of trisomy 21 or whether, being
present in the adult brain, they reflect cumulative changes
resulting from the many DS pathologies.
Despite some overlap with the published data from fetal DS
brain, overexpression of many of the trisomic genes was
previously unconfirmed in humans with DS. Functional pro-
filing of transcripts that are dysregulated in the DS brain has
provided some insights into processes that may be important in
the syndrome; however, the role played by triplication of genes
on chromosome 21 in triggering the processes involved has yet
to be elucidated.
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Tissue collection
Fresh-frozen prefrontal cortex tissue from 10Down syndrome and 3matched
control subjects was obtained from the Cambridge Brain Bank (Addenbrooke's
Hospital, Cambridge, UK). To increase statistical power, an additional 6 control
samples were included, obtained from the Neuropathology Consortium of the
Stanley brain collection (Stanley Medical Research Institute, USA). These were
selected from a group of 34 on the basis that they showed profiles similar to those
of the 3 matched control samples, assessed by principal components analysis.
Demographic and clinical data for the samples used in the analysis are provided
in Supplementary Table 1. The tissue was collected with full informed consent
obtained from a first-degree relative after death in compliance with the
Declaration of Helsinki. Ethics approval for brain collection is held by the
Stanley Medical Research Institute and ethics approval was received from the
Cambridge local research ethics committee for use of human postmortem tissue.
Acquisition and preprocessing of microarray data
All procedures have previously been described [62]. In brief, total RNAwas
extracted from all samples using Tri-reagent (Sigma) or Trizol (Gibco BRL) and
RNA quality was assessed using a high-resolution electrophoresis system
(Agilent Technologies). Isolated total RNA was then carried through the
Affymetrix preparation protocol (www.affymetrix.com) and each sample was
hybridized to one HG-U133A GeneChip (Affymetrix). The additional control
samples from the Stanley brain collection were run in the same laboratory but
separately from the initial set of 13 samples from the Cambridge Brain Bank.
Raw data were processed and analyzed using the R statistical program [63] and
Bioconductor [64] packages. Our rigorous quality control (QC) procedures [62]
included assessment of pairwise correlations between chips, box plots of robust
multichip average (RMA) normalized expression values for each chip, and
comparison of all chips to a pseudo-median chip. Based on these analyses, as well
as the assessment of RNA quality, three DS samples and one matched control
sample were considered outliers and excluded from further analysis. Thus, the
final analysis was based upon seven DS and eight control samples. Normalized
expression values (log base 2) for chips passing QC were computed using the
RMA method [65], which has been shown to detect expression levels reliably,
independent of signal intensity (out-performing MAS5.0 (Affymetrix) and the
Model Based Expression Index [66] as well as being more sensitive for the
detection of differentially expressed genes [67]). The gene expressionmatrix was
filtered to exclude control probe sets and to include only probe sets that had a
“class A” assignment (Affymetrix annotation file, December 2005), which are
most specific to the target transcript sequence. This filtering step reduced the gene
expression matrix to 19,759 probe sets.
Raw microarray data have been deposited with GEO (Accession No.
GSE5390).
Detection of differentially expressed genes
A Bayesian moderated t test was applied to identify differentially expressed
genes using the LIMMA (linear models for microarray analysis) package [68]
from Bioconductor. The Benjamini–Hochberg false discovery rate (FDR) [69]
was applied to correct for multiple testing. Adjusted p values are referred to as q
values throughout. To calculate fold changes, RMA expression values were
unlogged and the ratio of mean expression in the DS group to mean expression in
the control group was computed. Values less than 1, indicating decreased
expression in DS, were expressed as negative fold changes by multiplying the
control/DS ratio by −1.
Demographic variables
The inclusion of additional control samples had one adverse consequence in
that the disease and control samples were less well matched for demographic
variables than the original sample set. The correlation of differentially expressed
genes with age, gender, and PMI was determined to assess whether these
variables had any influence on gene expression. Pearson's correlation test wasused for age and PMI and a Student t test was used for gender. The p values were
adjusted using the Benjamini–Hochberg FDR correction [69].
QPCR validation
For quantitative real-time PCR, complementary DNAwas synthesized from
500 ng DNA-free RNAwith an oligonucleotide deoxythymidine primer and the
Superscript First-Strand Synthesis System (Invitrogen). QPCR was performed
using the Applied Biosystems 7900HT Sequence Detection System following
the manufacturer's instructions. Eleven genes were selected for validation using
TaqMan gene expression assays (Applied Biosystems), based on their location on
chromosome 21 (ADAMTS1, ADARB1, APP, DYRK1A, DSCR1, BACE2,
PTTG1IP, S100B) and/or their relevance to AD pathology (APOE, APPBP2,
NOTCH2). To avoid any potential DNA amplification that may have remained
after DNase treatment, chosen QPCR assays spanned intron–exon boundaries.
Additionally, the assays were designed to detect the same or very similar
transcript populations measured by the corresponding significant microarray
probe set. PGK1 was chosen as an endogenous control for the normalization of
all target genes as it was consistently expressed in microarray samples. There was
no significant difference in the cycle threshold (Ct) values for PGK1 between
disease and control groups (p = 0.40). Standard curves were constructed for each
assay to ensure amplification efficiencies were close to 100% and comparable
across all assays. The comparativeCt method was employed for quantification of
the transcript expression levels [70]. Triplicate Ct values were generated for all
assays; the median value in each case was used for subsequent analysis and
2−ΔΔCt values were then calculated. Two control samples were removed from the
dataset on the grounds of poor cDNA profiles. For each gene, a two-tailed
Student t test was used to determine whether the mean expression was
significantly different in the DS group compared to controls.
Comparison to DS fetal brain
A publicly available microarray dataset from human DS fetal cerebrum [21]
was used for comparison with the results from the adult DS brain. CEL files for
four DS and seven control subjects were downloaded from the Pevsner
Laboratory Web site (http://pevsnerlab.kennedykrieger.org/ds_cel_files.htm)
and the dataset was reanalyzed using the methods described above. We
compared the genes localized to chromosome 21 that were up-regulated in both
the fetal and the adult DS brain. These genes represent strong candidates for the
disorder as their overexpression is reported by independent studies and also
implies that the dosage increase is not compensated for in development or
adulthood.
Functional profiling
Affymetrix probe set IDs that were differentially expressed in adult DS brain
were mapped to Entrez IDs using Onto-Translate [71], and the list of unique
Entrez IDs was submitted to Onto-Express [72]. This software associates each
gene with its Gene Ontology (GO) terms and identifies GO categories that are
statistically overrepresented in the list of differentially expressed genes relative to
their representation on the chip. Up- and down-regulated lists were submitted
separately, using default settings (hypergeometric distribution and FDR
(Benjamini–Hochberg) correction) and the Affymetrix human HG-U133A
array as reference. GO categories with a corrected p value below 0.05 and
containing at least three genes were considered in the analysis.
The list of genes identified as differentially expressed in both fetal and adult
datasets was also analyzed using Onto-Express as described above, with the
exception that due to the smaller number of genes in this list, up- and down-
regulated genes were submitted together.
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